Medications for Paroxysmal Nocturnal Hemoglobinuria

6 results

  • bkemv

    (eculizumab-aeeb)
    Amgen Inc
    BKEMV is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AchR) antibody positive.

  • empaveli

    (Pegcetacoplan)
    Apellis Pharmaceuticals, Inc.
    EMPAVELI® is indicated for treating adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

  • fabhalta

    (iptacopan)
    Novartis Pharmaceuticals Corporation
    FABHALTA is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) and to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid progression, pending further confirmation of clinical benefits for IgAN.

  • piasky

    (Crovalimab)
    Genentech, Inc.
    PIASKY is indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adult and pediatric patients aged 13 years and older who weigh at least 40 kg.

  • soliris

    (ECULIZUMAB)
    Alexion Pharmaceuticals Inc.
    SOLIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) in patients six years or older who are anti-AChR antibody positive, and neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 antibody positive adults.

  • ultomiris

    (ravulizumab)
    Alexion Pharmaceuticals Inc.
    ULTOMIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) in patients aged one month and older, generalized myasthenia gravis (gMG) in AChR antibody-positive adults, and neuromyelitis optica spectrum disorder (NMOSD) in AQP4 antibody-positive adults.